Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
暂无分享,去创建一个
[1] J. Stockman. Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2012 .
[2] A. Sheffer,et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. , 2011, The Journal of allergy and clinical immunology.
[3] D. Khan. Hereditary angioedema: Historical aspects, classification, pathophysiology, clinical presentation, and laboratory diagnosis. , 2011, Allergy and asthma proceedings.
[4] M. Riedl. Update on the acute treatment of hereditary angioedema. , 2011, Allergy and asthma proceedings.
[5] M. Campion,et al. Response time for ecallantide treatment of acute hereditary angioedema attacks. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[6] W. Lumry,et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. , 2010, Allergy and asthma proceedings.
[7] B. Zuraw. The Pathophysiology of Hereditary Angioedema , 2010, The World Allergy Organization journal.
[8] A. Sheffer,et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.
[9] William H. Yang,et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.
[10] W. Lumry,et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[11] K. Bork,et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[12] A. Kaplan,et al. The bradykinin-forming cascade and its role in hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[13] J. Bernstein,et al. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability , 2010, Expert review of clinical immunology.
[14] J. Bernstein,et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. , 2009, The Journal of allergy and clinical immunology.
[15] K. Wyrwich,et al. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema , 2009, Quality of Life Research.
[16] B. Zuraw. Clinical practice. Hereditary angioedema. , 2008, The New England journal of medicine.
[17] J. Levy,et al. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema , 2006, Expert opinion on investigational drugs.
[18] K. Bork,et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.
[19] B. Zuraw. Current and future therapy for hereditary angioedema. , 2005, Clinical immunology.
[20] A. Davis. The pathophysiology of hereditary angioedema. , 2005, Clinical immunology.
[21] M. Cicardi,et al. Hereditary and Acquired C1‐Inhibitor Deficiency: Biological and Clinical Characteristics in 235 Patients , 1992, Medicine.
[22] A. Davis. C1 inhibitor and hereditary angioneurotic edema. , 1988, Annual review of immunology.
[23] E. Becker,et al. Hereditary angioneurotic edema: II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein , 1962 .